KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non Operating Income (2016 - 2017)

Historic Non Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 3 years, with Q1 2017 value amounting to -$1.5 million.

  • Jazz Pharmaceuticals' Non Operating Income fell 7875.46% to -$1.5 million in Q1 2017 from the same period last year, while for Mar 2017 it was -$3.0 million, marking a year-over-year decrease of 8727.61%. This contributed to the annual value of $1.4 million for FY2015, which is 8335.83% down from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Non Operating Income stood at -$1.5 million for Q1 2017, which was down 7875.46% from -$749000.0 recorded in Q3 2016.
  • In the past 5 years, Jazz Pharmaceuticals' Non Operating Income ranged from a high of $2.2 million in Q1 2015 and a low of -$1.9 million during Q2 2015
  • Moreover, its 3-year median value for Non Operating Income was -$819000.0 (2016), whereas its average is -$226714.3.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Non Operating Income showed a top increase of 2333.67% in 2016 and a maximum decrease of 13648.11% in 2016.
  • Jazz Pharmaceuticals' Non Operating Income (Quarter) stood at $2.1 million in 2015, then plummeted by 135.82% to -$749000.0 in 2016, then plummeted by 95.46% to -$1.5 million in 2017.
  • Its Non Operating Income was -$1.5 million in Q1 2017, compared to -$749000.0 in Q3 2016 and -$819000.0 in Q1 2016.